Crown Bioscience Enhances Oncology Research with New Facility

Crown Bioscience Enhances Oncology Research with Facility Expansion

Crown Bioscience, a leading global contract research organization (CRO) known for its commitment to advancing human health, has announced the expansion of its Singapore facility. This move marks a significant step in expanding its capabilities in oncology research, incorporating advanced imaging technologies and innovative models for drug discovery. The company has recently become a part of JSR Life Sciences and is now under the stewardship of Japan Investment Corporation Capital Co., Ltd. (JICC).

Strategic Location for Enhanced Services

The expanded facility, situated within a thriving hub for biomedical sciences, positions Crown Bioscience to better serve both local and international biotech as well as pharmaceutical companies. This facility is pivotal in supporting preclinical and translational oncology drug development, enhancing the company’s already impressive global presence which includes 12 strategic locations worldwide.

Innovative Technologies to Drive Discovery

At the forefront of this expansion are cutting-edge technologies. The Singapore facility is equipped with state-of-the-art Magnetic Resonance Imaging (MRI) capabilities for orthotopic and systemic models, allowing researchers to visualize and assess treatment effectiveness in real time. Other advanced instruments include In Vivo Imaging Systems (IVIS) as well as the innovative MiXeno™ platform that supports human immunity studies.

Comprehensive Oncology Models Available

Crown Bioscience is committed to offering an extensive selection of oncology models crucial for understanding cancer therapies. With a focus on in vivo research, the facility provides syngeneic, cell-derived xenografts (CDX), and patient-derived xenografts (PDX) models. These services are designed to meet the diverse needs of researchers aiming to evaluate the efficacy of novel drugs in a realistic biological context.

Insights from Leadership

During the announcement, John Gu, the Interim CEO of Crown Bioscience, expressed enthusiasm about the facility's expansion. He mentioned, “The expansion of our Singapore facility not only amplifies our oncology research capabilities but also reflects our strategic initiative to diversify our global operational bases and enhance accessibility in key regions. This ensures that we can continue to provide our clients with unmatched precision and efficiency in preclinical and translational drug research and development.”

A Commitment to Personalized Medicine

Crown Bioscience’s dedication to improving healthcare doesn't stop with laboratory research. The company is actively involved in personalized medicine initiatives, leveraging their subsidiary, Indivumed Services, to maintain a comprehensive biobank of human biospecimens. By doing so, they ensure a robust foundation for their clients’ research into personalized therapies.

Organ Development Expertise

Additionally, the company offers unique preclinical tumor organoid services, utilizing the acclaimed Hubrecht Organoid Technology. With over 600 organoid models available across 22 cancer indications, Crown Bioscience stands out as having the largest collection of commercially available PDX models worldwide. This commitment to research innovation reinforces their ambition to support clients in developing effective therapies.

Looking Ahead

Founded in 2006, Crown Bioscience has firmly established itself as a front-runner in the CRO industry, operating facilities across the US, Europe, and Asia. As they continue to grow and expand their capabilities, the firm remains dedicated to fostering partnerships with biotech and pharmaceutical companies, ultimately working towards the goal of ensuring patients receive timely and effective treatments.

Frequently Asked Questions

What is Crown Bioscience’s primary focus?

Crown Bioscience focuses on oncology research and drug discovery, aiming to support the development of therapies that improve human health.

Where is the newly expanded facility located?

The new facility is located in Singapore, within Asia's biomedical sciences hub, enhancing the company's support for oncology research.

What innovative technologies does the Singapore facility offer?

The facility features advanced imaging technologies like Magnetic Resonance Imaging (MRI) and In Vivo Imaging Systems (IVIS) to aid in cancer research.

What are PDX and CDX models?

PDX (Patient-Derived Xenograft) and CDX (Cell-Derived Xenograft) models are pivotal for researching cancers as they mimic real human tumors more closely for drug testing.

How does Crown Bioscience contribute to personalized medicine?

Crown Bioscience supports personalized medicine through its extensive biobank and organoid models, enabling tailored treatment strategies for patients.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.